TuHURA Biosciences

[TuHURA Biosciences @HURA_IR]

response in situ to all neoantigens present in the injected tumor compared to trying to predict which neoantigens are important to a patient generated anti-tumor immune response.

$MRNA $MRK

[TuHURA Biosciences @HURA_IR]

$HURA Intismeran and IFx-2.0 take very different approaches to generating a patient-specific antitumor immune response.

[TuHURA Biosciences @HURA_IR]

neoantigens and importantly doesn’t require 6 to 9 weeks for each patient’s treatment tIt is immediately available to patients and injected directly into the tumor designed to use the patient’s own tumor as the neoantigen source, initiating the immune

[TuHURA Biosciences @HURA_IR]

manufactured therapy for each patient.

$MRNA $MRK

[TuHURA Biosciences @HURA_IR]

$HURA Merck and Moderna’s positive Phase 3 results for intismeran autogene plus KEYTRUDA are an encouraging development for patient-specific cancer immunotherapy.

[TuHURA Biosciences @HURA_IR]

Intismeran uses sequencing and predictive selection to identify specific neoantigens for an individualized mRNA therapy, while IFx-2.0 is injected directly into the tumor and designed to expose the immune system to the neoantigens present there without requiring a separately

[TuHURA Biosciences @HURA_IR]

Watch the full presentation: https://t.co/4camMUbTwJ

[TuHURA Biosciences @HURA_IR]

$HURA The Canaccord presentation gave investors a clearer view of the clinical sequence taking shape across TuHURA’s pipeline.

[TuHURA Biosciences @HURA_IR]

For retail investors following the story, the key point is how these programs build around a common focus: addressing resistance to cancer immunotherapies.